These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
196 related items for PubMed ID: 1720019
1. A modified Arg-Asp-Val (RDV) peptide derived during the synthesis of Arg-Glu-Asp-Val (REDV), a tetrapeptide derived from an alternatively spliced site in fibronectin, inhibits the binding of fibrinogen, fibronectin, von Willebrand factor and vitronectin to activated platelets. Chen CS, Papayannopoulos IA, Timmons S, Chou SH, Thiagarajan P. Biochim Biophys Acta; 1991 Oct 31; 1075(3):237-47. PubMed ID: 1720019 [Abstract] [Full Text] [Related]
2. Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets. Ruggeri ZM, Houghten RA, Russell SR, Zimmerman TS. Proc Natl Acad Sci U S A; 1986 Aug 31; 83(15):5708-12. PubMed ID: 3016716 [Abstract] [Full Text] [Related]
3. How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Mohri H, Ohkubo T. Am J Clin Pathol; 1991 Nov 31; 96(5):605-9. PubMed ID: 1719797 [Abstract] [Full Text] [Related]
4. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. Gartner TK, Bennett JS. J Biol Chem; 1985 Oct 05; 260(22):11891-4. PubMed ID: 2995350 [Abstract] [Full Text] [Related]
12. Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin. Haverstick DM, Cowan JF, Yamada KM, Santoro SA. Blood; 1985 Oct 05; 66(4):946-52. PubMed ID: 3876125 [Abstract] [Full Text] [Related]
13. Novel effect of cyclicization of the Arg-Gly-Asp-containing peptide on vitronectin binding to platelets. Mohri H, Hashimoto Y, Ohba M, Kumagai H, Ohkubo T. Am J Hematol; 1991 May 05; 37(1):14-9. PubMed ID: 1708943 [Abstract] [Full Text] [Related]
14. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp. Varon D, Lider O, Dardik R, Shenkman B, Alon R, Hershkoviz R, Kapustina G, Savion N, Martinowitz U, Greenspoon N. Thromb Haemost; 1993 Dec 20; 70(6):1030-6. PubMed ID: 8165596 [Abstract] [Full Text] [Related]
15. KRDS, a new peptide derived from human lactotransferrin, inhibits platelet aggregation and release reaction. Mazoyer E, Lévy-Toledano S, Rendu F, Hermant L, Lu H, Fiat AM, Jollès P, Caen J. Eur J Biochem; 1990 Nov 26; 194(1):43-9. PubMed ID: 2174781 [Abstract] [Full Text] [Related]
16. Inhibition of human platelet aggregation by GR91669, a prototype fibrinogen receptor antagonist. Foster MR, Hornby EJ, Brown S, Hann M, Kitchin J, Pike N, Ward P. Thromb Res; 1994 Aug 01; 75(3):269-84. PubMed ID: 7992238 [Abstract] [Full Text] [Related]